<DOC>
	<DOCNO>NCT02192489</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics preliminary efficacy oral CC-220 adult subject chronic cutaneous sarcoidosis .</brief_summary>
	<brief_title>A Phase 2 Study With CC-220 Skin Sarcoidosis</brief_title>
	<detailed_description>This Phase 2a , multicenter , randomize , double-blind , placebo-controlled , sequential , dose-ascending , safety tolerability study subject chronic cutaneous sarcoidosis . Two dose cohort CC-220 ( Cohort 1 : 0.3 mg mouth ( PO ) every day ( QD ) match placebo Cohort 2 : 0.6 mg PO QD match placebo ) evaluate use sequential , dose-ascending design</detailed_description>
	<mesh_term>Sarcoidosis</mesh_term>
	<criteria>Males female age ≥ 18 year time consent . Have chronic cutaneous sacrcoidosis ( CCS ) prior consent Have active cutaneous sarcoidosis lesion ( ) screening Forced vital capacity ≥ 45 % predict normal value screen . Estimated Glomerular Filtration Rate ( eGFR ) ≥ 60 mL/min . Females childbearing potential must negative pregnancy test prior start study therapy agree either commit true abstinence use effective contraception . Male subject must practice true abstinence agree use condom even undergone successful vasectomy Positive tuberculosis test screening . History inadequately treat tuberculosis History Human Immunodeficiency Virus ( HIV ) and/or Common Variable Immunodeficiency Disease . History alcohol drug abuse History current peripheral neuropathy Current uveitis clinically significant ophthalmological finding Currently require therapy precapillary pulmonary hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic Cutaneous Sarcoidosis</keyword>
	<keyword>Cutaneous Sarcoidosis</keyword>
	<keyword>Skin Sarcoidosis</keyword>
	<keyword>Sarcoidosis</keyword>
</DOC>